Daily Stock Analysis, CBMG, Cellular Biomedicine Group Inc, priceseries

Cellular Biomedicine Group Inc. Daily Stock Analysis
Stock Information
Open
10.31
Close
10.55
High
10.65
Low
10.31
Previous Close
10.50
Daily Price Gain
0.05
YTD High
13.80
YTD High Date
Mar 2, 2017
YTD Low
5.05
YTD Low Date
May 12, 2017
YTD Price Change
-2.65
YTD Gain
-20.08%
52 Week High
13.80
52 Week High Date
Mar 2, 2017
52 Week Low
5.05
52 Week Low Date
May 12, 2017
52 Week Price Change
-2.95
52 Week Gain
-21.85%
Company Information
Stock Symbol
CBMG
Exchange
NasdaqGM
Company URL
http://www.cellbiomedgroup.com
Company Phone
(408) 973-7884
CEO
Bizuo Liu
Headquarters
California
Business Address
19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO, CA 95014
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001378624
About

Cellular Biomedicine Group, Inc. is a biopharmaceutical company. The company engages in the development of treatments for degenerative and cancerous diseases utilizing proprietary cell-based technologies. Its technology include immune cell therapy for treatment of a range of cancers using Chimeric Antigen Receptor T cell, cancer vaccine, and T Central Memory cell technology; and human adipose-derived mesenchymal progenitor cells for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. Cellular Biomedicine Group was founded in 2009 and is headquartered in Cupertino, CA.

Description

Cellular Biomedicine Group, Inc., a biomedicine company, develops treatments for cancerous and degenerative diseases in Greater China. The company operates through two segments, Biomedicine and Consulting. It focuses on developing and marketing cell-based therapies to treat serious chronic and degenerative diseases, such as cancer, osteoarthritis, tissue damage, spinal muscular atrophy, various inflammatory diseases, and joint degeneration and metabolic diseases. The company develops treatments utilizing proprietary cell technologies comprising tumor cell specific dendritic cells for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint disease; human umbilical cord-derived mesenchymal progenitor cells; human embryo-derived motor neuron progenitor precursor cells; and human embryo-derived neuronal progenitor precursor cells for the treatment of central nervous system diseases. It also provides consulting services to companies who seek access to the U.S. capital markets. The company is headquartered in Palo Alto, California.